Compare Merck & Co., Inc. (MRK) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Spotify Technology — how do they compare? Merck & Co., Inc. trades at $132.94 (market cap $321.77B), while Spotify Technology trades at $489.8 (market cap $103.00B). The key difference: Merck & Co., Inc. is far larger — about 3.1× Spotify Technology's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Spotify Technology pays none. Which is the better fit depends on your goals.
| MRK | SPOT | |
|---|---|---|
Market Cap | $321.77B | $103.00B |
Sector | Health | Media |
52-Week High | $131.84 | $738.53 |
52-Week Low | $77.60 | $412.75 |
Enterprise Value | $368.53B | $92.70B |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Spotify (SPOT) trades at $489.65, down 4.33% in the last session, amid mixed technical signals and strong fundamentals. The stock shows a bullish moving average trend but neutral oscillators, with key support at $487. Financially, revenue grew to $17.19B in 2025 with a net income margin of 12.87%, while recent news highlights initiatives like AI artist labeling to enhance transparency.
Outlook remains positive with a consensus price target of $598.20, implying 22% upside, driven by subscriber growth and margin expansion. Risks include competitive pressures and cost management, but analyst sentiment is bullish with 62% buy ratings, supporting long-term value for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
